common.study.topics.clinical

Testing Experimental Treatment for Multiple Myeloma

common.study.values.description

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) and schedules for each combination (combination 1: daratumumab and JNJ-64407564 [anti-GPRC5DxCD3] or combination 2: daratumumab and JNJ-64007957 [anti-BCMAxCD3]) and to characterize the safety of each RP2D for each combination.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Daratumumab

Participants will receive daratumumab SC.

Drug - JNJ-64407564

Participants will receive JNJ-64407564 IV.

Drug - JNJ-64007957

Participants will receive JNJ-64007957 IV.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma

common.study.values.clinical-trial-id

NCT04108195

participant.views.study.view.id

e9rWxa